DENVER, CO — January 13, 2026 — Leads & Copy — Aytu BioPharma, Inc. (Nasdaq: AYTU) announced that CEO Josh Disbrow will participate in a fireside chat at the Lytham Partners 2026 Investor Healthcare Summit.
The webcast, moderated by Thomas Flaten, Senior Research Analyst at Lake Street Capital Markets, is scheduled for January 15, 2026, at 5:00 p.m. Eastern time.
Interested parties can access the webcast via the conference homepage or directly through the provided link. A replay will be available through the same links.
Aytu BioPharma focuses on advancing innovative medicines for complex central nervous system diseases, aiming to improve patients’ quality of life. The company’s prescription products include EXXUA™ (gepirone) extended-release tablets for treating major depressive disorder (MDD) and treatments for attention deficit-hyperactivity disorder (ADHD). Aytu is committed to ensuring optimal patient outcomes through patient access programs.
Ryan Selhorn, Chief Financial Officer of Aytu BioPharma, Inc., can be reached at rselhorn@aytubio.com. Robert Blum from Lytham Partners can be contacted at aytu@lythampartners.com.
Source: Aytu BioPharma, Inc.
